114
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Development and Characterization of a Novel Carbon-11 Labeled Positron Emission Tomography Radiotracer for Neuroimaging of Sirtuin 1 with Benzoxazine-Based Compounds

, ORCID Icon, , , , , , & show all
Pages 819-827 | Received 10 Oct 2023, Accepted 16 Jan 2024, Published online: 14 Mar 2024

References

  • Jing H, Lin H. Sirtuins in epigenetic regulation. Chem Rev. 2015;115(6):2350–2375. doi:10.1021/cr500457h
  • Cantó C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009;20(7):325–331. doi:10.1016/j.tem.2009.03.008
  • Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81(3):471–483. doi:10.1016/j.neuron.2014.01.028
  • O’Callaghan C, Vassilopoulos A. Sirtuins at the crossroads of stemness, aging, and cancer. Aging Cell. 2017;16(6):1208–1218. doi:10.1111/acel.12685
  • Fujita Y, Yamashita T. Sirtuins in neuroendocrine regulation and neurological diseases. Front Neurosci. 2018;12:778. doi:10.3389/fnins.2018.00778
  • Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–622. doi:10.1016/j.cmet.2011.10.002
  • Marcotte PA, Richardson PL, Guo J, et al. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal Biochem. 2004;332(1):90–99. doi:10.1016/j.ab.2004.05.039
  • Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010;285(11):8340–8351. doi:10.1074/jbc.M109.088682
  • Dai H, Kustigian L, Carney D, et al. SIRT1 activation by small molecules-kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem. 2010;285(43):32695–32703. doi:10.1074/jbc.M110.133892
  • Süssmuth SD, Haider S, Landwehrmeyer GB, et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br J Clin Pharmacol. 2015;79(3):465–476. doi:10.1111/bcp.12512
  • Broussy S, Laaroussi H, Vidal M. Biochemical mechanism and biological effects of the inhibition of silent information regulator 1 (SIRT1) by EX-527 (SEN0014196 or selisistat). J Enzyme Inhib Med Chem. 2020;35(1):1124–1136. doi:10.1080/14756366.2020.1758691
  • Suridjan I, Comley RA, Rabiner EA. The application of positron emission tomography (PET) imaging in CNS drug development. Brain Imaging Behav. 2019;13(2):354–365. doi:10.1007/s11682-018-9967-0
  • Bonomi R, Popov V, Laws MT, et al. Molecular imaging of sirtuin1 expression-activity in rat brain using positron-emission tomography-magnetic-resonance imaging with [18F]-2-fluorobenzoylaminohexanoicanilide. J Med Chem. 2018;61(16):7116–7130. doi:10.1021/acs.jmedchem.8b00253
  • Xu Y, Chen Z, Wey H-Y, et al. Molecular imaging of NAD+-dependent deacetylase SIRT1 in the brain. Alzheimers Dement. 2021;17(12):1988–1997. doi:10.1002/alz.12344
  • Chen Z, Wang X, Xu Y, Wang C. Synthesis of 11C-labeled DNA polymerase-β inhibitor 5-methoxyflavone and PET/CT imaging thereof. Nucl Med Biol. 2019;78–79:17–22. doi:10.1016/j.nucmedbio.2019.10.005
  • Xu Y, Wang Y, Wang H, Wang C. Synthesis and characterization of carbon-11 labeled iloperidone for imaging of α1-adrenoceptor in brain. Front Mol Biosci. 2020;7:586327. doi:10.3389/fmolb.2020.586327
  • Xu Y, Wang C, Wey H-Y, et al. Molecular imaging of Alzheimer’s disease-related gamma-secretase in mice and nonhuman primates. J Exp Med. 2020;217(12):e20182266. doi:10.1084/jem.20182266
  • Spinck M, Bischoff M, Lampe P, Meyer-Almes F-J, Sievers S, Neumann H. Discovery of dihydro-1,4-benzoxazine carboxamides as potent and highly selective inhibitors of sirtuin‑1. J Med Chem. 2021;64(9):5838–5849. doi:10.1021/acs.jmedchem.1c00017
  • Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of drug-like properties. ACS Chem Neurosci. 2010;1(6):435–449. doi:10.1021/cn100008c
  • Van de Bittner GC, Ricq EL, Hooker JM. A philosophy for CNS radiotracer design. Acc Chem Res. 2014;47(10):3127–3134. doi:10.1021/ar500233s